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 Advances in the science of statistics as well 
as the availability of accessible statistical 
soft ware have facilitated the analysis of 
clinical data using complex models. Com-
plex statistical models are oft en perplex-
ing, with bewildering nomenclature and 
analysis that impede understanding of the 
statistical methods and interpretation of 
the results. However, papers that use these 
models also present an opportunity to 
learn statistical concepts, which I will 
attempt to facilitate in this Commentary. 
 Th e paper by Weir  et al. 1 (this issue) 
asks a simple but important question: 
among blacks with chronic kidney disease 
(CKD), compared with the combination 
antihypertensive therapy of an angio-
tensin-converting enzyme (ACE) inhib-
itor plus hydrochlorothiazide (HCTZ), 
does the combination therapy of an ACE 
inhibitor with amlodipine provide supe-
rior renal protection? Because nearly 
all blacks were recruited from the 
United States, these analyses apply to the 
US data only. Th e data were analyzed  post 
hoc from a randomized trial called Avoid-
ing Cardiovascular Events Th rough Com-
bination Th erapy in Patients Living with 
Systolic Hypertension (ACCOMPLISH). 
Th is trial recruited hypertensive patients 
who were at a high risk for cardiovascular 
events and randomly assigned them to one 
of two combination therapies: benazepril 
plus HCTZ or benazepril plus amlodipine. 
Th e primary outcome of this trial was a 
composite of hard cardiovascular events 
and has previously been reported. 2 
 In the analysis reported, of the nine pre-
specifi ed primary adjudicated end points, 
none achieved a nominal significance 
value less than 0.05. Two of these adjudi-
cated end points were renal outcomes and 
were also negative. However, the authors 
appropriately reasoned that outcomes that 
were more sensitive than end-stage renal 
disease to detect progression of CKD were 
needed. Th ey therefore proposed a more 
sensitive end point related to progression 
of CKD. Instead of doubling of serum cre-
atinine (a 100 % increase), they proposed 
that progression of CKD be defi ned by at 
least a 50 % increase in serum creatinine 
concentration over the course of the trial. 
Th e  post hoc outcomes to evaluate renal 
protection were several — seven in all. 
 False positives and multiple comparisons: 
answers with simulation 
 With seven outcomes, the nominal  P -value 
of   <  0.05 is likely to have a high false-positive 
rate. How can we estimate this likelihood of 
high false positive? One can use statistical 
textbooks to fi nd the formulae or fall back 
to the statistical soft ware to make these cal-
culations. Although the formulae are useful, 
they are not as intuitive. One very powerful 
tool is simulation. It can also improve one ’ s 
understanding of statistics. In order to per-
form a simulation to answer this question, 
using statistical soft ware (Stata / SE 11.2, 
Stata Corp.), I simply created a large ima-
ginary data set of 10,000 obser vations and 
populated this from draws from a random 
normal distribution. For each of the seven 
imaginary outcomes, I assigned the top and 
bottom 2.5 % of observations as success and 
the remaining 95 % as failure. I then counted 
how many times I had at least one success 
across the seven comparisons. Using this 
simulation, I found that the positive rate by 
chance alone would be 30.2 % if the  P -value 
were set at 0.05. Intuitively, the more com-
parisons we have, the greater the likelihood 
of a success or false positivity. Th e likelihood 
of success by simulation was as follows: for 
two comparisons, 9.8 % ; for three, 14.3 % ; 
for four, 18.5 % ; for fi ve, 22.6 % ; and for six, 
26.5 % . What would the  P -value need to be 
to protect from the false-positive error? Th e 
Bonferroni correction (nominal  P -value 
divided by number of comparisons) — 
about 0.007 for seven comparisons — would 
protect from this false-positive error. By 
simulation, the false-positive rate aft er Bon-
ferroni correction was 0.049, which is what 
we would have predicted. 
 In the study by Weir  et al. , 1 all of the 
seven  post hoc outcomes failed to achieve 
statistical signifi cance except one. Th is 
positive outcome, a greater than 50 % 
increase in serum creatinine concentration 
from baseline reaching a serum creatinine 
concentration greater than 2.6  mg / dl, was 
seen in 2.1 % of 1414 blacks and 1.2 % of 
6738 non-blacks. The  P -value for this 
positive comparison was 0.001. Th is fi nd-
ing demonstrates a greater progression of 
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CKD among blacks. Furthermore, in con-
trast to the propensity for CKD progres-
sion, blacks had a lower propensity for 
cardiovascular disease than non-blacks. 
Although this outcome may pass statisti-
cally for multiple comparison, this result 
does not address the original question 
posed — whether one therapy is superior 
to the other in blacks versus non-blacks. 
To answer this question, we will have to 
further analyze the data for progressive 
albuminuria and progression by estimated 
glomerular fi ltration rate (eGFR). 
 Interaction eff ects and ordered categorical 
data 
 Before we address the above question, it 
must be noted that the hard outcomes of 
end-stage renal disease and death among 
blacks were never achieved. Th e study was 
not designed to address this end point 
in people with at least moderate kidney 
disease. Also, the study was terminated 
early, so it did not have suffi  cient power 
to detect this outcome. Accordingly, the 
progression of CKD was determined by 
surrogate end points. 
 Albuminuria, widely used as a surrogate 
end point in clinical trials, was measured as 
an outcome. To classify albuminuria, the 
investigators, using standard defi nitions, 
assigned albuminuria in three categories: no 
albuminuria, microalbuminuria, and mac-
roalbuminuria. Baseline albuminuria and 
maximal albuminuria aft er treatment were 
provided, and this information can be used 
to calculate the probability of albuminuria 
from baseline to end of trial. Th e investiga-
tors used the Cochran – Mantel – Haenszel 
statistic to analyze this information. While 
this statistic is appropriate for analysis 
of stratified categorical data, it does not 
make use of the ordered nature of informa-
tion. Given that there was an ordered 
outcome in albuminuria (none  micro
  macro), we can use ordinal logistic 
regression as a statistical tool to defi ne CKD 
progression. Increasing albuminuria in this 
model would therefore predict increasing 
risk of CKD progression. Albuminuria can 
be aff ected by the drug combination used 
(amlodipine-based or HCTZ-based) as a 
function of time. If albuminuria is reduced 
by one drug and increased by another, the 
statistical interaction of treatment × time 
would be signifi cant. If this interaction is 
aff ected by ethnicity, then the three-way 
interaction (ethnicity × treatment × time) 
would also be signifi cant. Ordinal logistic 
regression tests for additive interaction, but 
we can examine for multiplicative interac-
tion as well. Using the data provided by 
Weir  et al. , 1 in the multiplicative intera ction 
model, the odds ratio for drug × time inter-
action was signifi cant ( P  =  0.033). Perhaps 
it is easier to appreciate the inter action eff ect 
from the predicted probability of events 
aft er modeling the data.  Figure 1 shows that 
among those who received the HCTZ-
based regimen (blue line), the probability of 
macroalbuminuria and microalbuminuria 
was reduced and the probability of no albu-
minuria increased. In the case of the 
amlodipine-based regimen, the results were 
the converse. Th ere was no modifi cation of 
this effect by ethnicity ( P  =  0.73 for the 
three-way interaction of ethnicity × drug × 
time). Visual examination of the fall in 
macro albuminuria and microalbuminuria 
among blacks and non-blacks also supports 
the lack of interaction. Thus, the results 
were no different between blacks and 
non-blacks. Although more nuanced analy-
ses are possible for ordinal data that also 
account for correlated observations from 
before to aft er treatment within subjects, 
this was not possible, as the primary data 
were not available. Nonetheless, the analy-
ses reported here are supported by 
the results on albuminuria reported in the 
overall study of renal outcomes. 3 
 Another example of interaction (or lack 
thereof) using continuous data 
 Progression in eGFR was next evaluated. 
Th e investigators were aware of the diff er-
ences in acute hemodynamic changes 
that can occur with HCTZ- versus amlo-
dipine-based therapies. Th ey therefore 
focused on the change in eGFR from 
3 months to the end of the trial. Th e 
decline in eGFR from 3 months to end of 
trial was calculated by mixed models that 
are by themselves quite complex and are 
discussed elsewhere. 4 However, to illus-
trate the CKD progression, the rates of 
decline reported by the authors from these 
mixed models are depicted in  Figure 2 . 
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 Figure 1  |  Probability of albuminuria by categories from baseline to post-treatment among 
blacks and non-blacks, derived from the multiplicative ordinal logistic regression model. 
The predictive terms were ethnicity, drug, and time and all possible interactions in this model. 
The outcome was the change in category of albuminuria. Blue lines represent the combination of 
benazepril and hydrochlorothiazide (B  +  H), whereas red lines show the results of the combination 
of benazepril and amlodipine (B  +  A). The drug × time interaction was significant, but the three-way 
interaction (ethnicity × drug × time) was not. Post-Rx, post-treatment. 
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Overall, the rates of fall in eGFR were 
small. Among non-blacks they favored the 
amlodipine-based therapy by 0.03  ml / min 
per month. Th is amounts to loss of eGFR 
annually of less than 0.5  ml / min. Among 
blacks there was no detectable diff erence 
between therapies. Th e interaction eff ects, 
although not reported, are unlikely to be 
statistically signifi cant. Even if they were, 
their clinical signifi cance would be small. 
 Interpreting the trial results: the lessons 
 Th e idea that amlodipine-based therapy 
can achieve superior renal protection 
should be accepted with great caution, 
for two reasons. First, this trial found that 
CKD pro gression, when defi ned by a 50 % 
increase in creatinine achieving a serum 
creatinine concentration of 2.6  mg / dl, was 
greater among blacks than non-blacks. 
However, between blacks and non-blacks 
the mean change in eGFR calculated as slopes 
either from baseline or from 3 months 
until the end of study was no diff erent. 
Th us, statistical inference of CKD progres-
sion depends on the methodo logy used 
to defi ne progression. Second, there is 
at least one notable example of discre pant 
results regarding renal protection calculat-
ed with eGFR in patients with mild to mod-
erate CKD versus patients with hard renal 
end points with more advanced CKD. In 
the Heart Protection Study, patients had 
at most mild to moderate CKD; in this 
trial simvastatin was found to protect 
from a decline in eGFR. 5 In the Study of 
Heart and Renal Protection (SHARP), 
which randomized patients with more sub-
stantial CKD to a combination therapy of 
simvastatin and ezetimibe or placebo, no 
signal of renal protection was found. 6 In 
the latter trial, end-stage renal disease was 
used as an outcome measure. 
 What can we conclude from the study by 
Weir  et al. ? 1 Th e authors have previously 
reported that blacks have a greater likeli-
hood of having CKD. 2 An important fi nd-
ing of this study is that, compared with 
non-blacks, US blacks appear to have a 
greater propensity for CKD progression, 
but a lesser propensity for cardiovascular 
morbidity and mortality. Also, compared 
with non-blacks, blacks had poorer blood 
pressure control. Over the course of the 
trial, on average, blacks had 4.5 / 3.9  mm  Hg 
higher BP in the amlodipine-based group, 
and 4.2 / 3.2  mm  Hg higher BP in the 
HCTZ-based group. Although the statisti-
cal signifi cance of these elevations is not 
reported, the ACCOMPLISH study previ-
ously reported that Caucasians had better 
BP control. 7 With respect to hard renal 
outcomes among black patients who had 
at most mild to moderate kidney disease, 
no diff erences were found between com-
bination therapies. Th e amlodipine-based 
regimen was not clinically superior to the 
HCTZ-based regimen in protecting from 
a decline in eGFR. In contrast, the HCTZ-
based regimen appeared to be better for 
reducing albuminuria. We should remain 
cautious in extrapolating these results 
obtained in patients with mild to moderate 
CKD to later stages of kidney disease. How 
will the results of this trial change my prac-
tice? I will continue to use both drugs — 
HCTZ and amlodipine — as needed for 
black patients with CKD. Why US blacks 
are more likely to have progressive CKD 
and less likely to have cardiovascular 
events will require further research. 
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